Enanta Pharmaceuticals is a biotechnology company that focuses on small molecule drugs for viral infections and liver diseases. Enanta’s research is currently focused on the following disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV). The company has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.